These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 15183042

  • 1. The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitor.
    Kondo N, Wakayama F, Suzuki Y, Fukui K, Takaya S, Fukuda I.
    Thromb Res; 2004; 113(5):303-10. PubMed ID: 15183042
    [Abstract] [Full Text] [Related]

  • 2. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.
    Straub A, Schiebold D, Wendel HP, Azevedo R, Dietz K, Ziemer G.
    Thromb Res; 2008; 122(3):383-9. PubMed ID: 18304613
    [Abstract] [Full Text] [Related]

  • 3. Platelet preservation with a glycoprotein IIb/IIIa inhibitor in a porcine cardiopulmonary bypass model.
    Kondo N, Suzuki Y, Wakayama F, Tamai Y, Ji K, Fukui K, Fukuda I.
    Ann Thorac Surg; 2005 Jul; 80(1):251-7. PubMed ID: 15975376
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass.
    Tabata S, Yamaguchi S, Nagamine H, Tomita S, Arai S, Takemura H, Watanabe G.
    Eur J Cardiothorac Surg; 2004 Aug; 26(2):289-93. PubMed ID: 15296885
    [Abstract] [Full Text] [Related]

  • 5. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
    Straub A, Wendel HP, Dietz K, Schiebold D, Peter K, Schoenwaelder SM, Ziemer G.
    Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
    [Abstract] [Full Text] [Related]

  • 6. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation.
    Kanemitsu S, Nishikawa M, Onoda K, Shimono T, Shimpo H, Yazaki A, Tanaka K, Shiku H, Yada I.
    J Thorac Cardiovasc Surg; 2003 Aug; 126(2):428-35. PubMed ID: 12928640
    [Abstract] [Full Text] [Related]

  • 7. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J.
    J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
    [Abstract] [Full Text] [Related]

  • 8. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
    Kozek-Langenecker SA, Spiss CK, Michalek-Sauberer A, Felfernig M, Zimpfer M.
    Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
    [Abstract] [Full Text] [Related]

  • 9. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
    Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds LH.
    J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
    [Abstract] [Full Text] [Related]

  • 10. A defined peptide that inhibits the formation of the glycoprotein IIb and IIIa complex.
    Chiang TM, Zhu J.
    Thromb Res; 2005 Jul; 115(6):503-8. PubMed ID: 15792682
    [Abstract] [Full Text] [Related]

  • 11. Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation.
    Wachtfogel YT, Kettner C, Hack CE, Nuijens JH, Reilly TM, Knabb RM, Kucich U, Niewiarowski S, Edmunds LH, Colman RW.
    Thromb Haemost; 1998 Oct; 80(4):686-91. PubMed ID: 9798991
    [Abstract] [Full Text] [Related]

  • 12. Thrombogenesis in sickle cell disease.
    Tomer A, Harker LA, Kasey S, Eckman JR.
    J Lab Clin Med; 2001 Jun; 137(6):398-407. PubMed ID: 11385360
    [Abstract] [Full Text] [Related]

  • 13. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
    Wang WY, Wu YC, Wu CC.
    Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.
    Goto S, Tamura N, Ishida H, Ruggeri ZM.
    J Am Coll Cardiol; 2006 Jan 03; 47(1):155-62. PubMed ID: 16386680
    [Abstract] [Full Text] [Related]

  • 16. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
    Straub A, Azevedo R, Beierlein W, Wendel HP, Dietz K, Ziemer G.
    Thorac Cardiovasc Surg; 2006 Apr 03; 54(3):162-7. PubMed ID: 16639676
    [Abstract] [Full Text] [Related]

  • 17. Platelet activation after stenting with heparin-coated versus noncoated stents.
    Gurbel PA, Bliden KP.
    Am Heart J; 2003 Oct 03; 146(4):E10. PubMed ID: 14564333
    [Abstract] [Full Text] [Related]

  • 18. Evidence for selective degradation of platelet GP IIb/IIIa complex after prolonged in vitro ventricular assist.
    Serna DL, King BO, Huh J, Jalal R, Tran L, Chen JC.
    J Investig Med; 1998 Aug 03; 46(6):279-83. PubMed ID: 9737089
    [Abstract] [Full Text] [Related]

  • 19. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
    Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL, Michelson AD.
    J Am Coll Cardiol; 2004 Jun 16; 43(12):2319-25. PubMed ID: 15193700
    [Abstract] [Full Text] [Related]

  • 20. Measurement of glycoprotein IIb/IIIa blockade by flow cytometry with fluorescein isothiocyanate-conjugated crotavirin, a member of disintegrins.
    Liu CZ, Hur BT, Huang TF.
    Thromb Haemost; 1996 Oct 16; 76(4):585-91. PubMed ID: 8903000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.